class = “sc-cffd1e67-0 fmXrkB”>
Milestone payments of up to $400 million can also be made. Carmot Therapeutics is a privately held company and has product candidates that could be used to treat obesity in patients with and without diabetes, according to a statement released Monday. These are all based on the novel GLP-1 mechanism of action, which has attracted intense media attention lately.
Recently, the drug Wegovy has caused a stir. It is a product of the Danish pharmaceutical company Novo Nordisk. It contains the active ingredient semaglutide, which supports weight loss in overweight people.
For example, Wegovy needs to be injected under the skin once a week. In obese patients without comorbid diabetes, Wegovy treatment can lead to weight loss of up to 15 percent over an 18-month treatment period. In principle, Wegovy increases the feeling of fullness, which reduces the calories consumed because patients have less hunger and appetite.
Other products in this field include Ozempic, also produced by Novo Nordisk, or Eli Lilly’s diabetes drug Mounjaro, which also provides weight loss.
With the acquisition of Carmot, Roche adds three more important GLP-1 product candidates to its portfolio. Two of the candidates will be tested to treat obesity in patients with and without type 2 diabetes, while the third will be used to treat type 1 diabetic patients who are overweight or obese.
(SDA)
Source :Blick
I’m Tim David and I work as an author for 24 Instant News, covering the Market section. With a Bachelor’s Degree in Journalism, my mission is to provide accurate, timely and insightful news coverage that helps our readers stay informed about the latest trends in the market. My writing style is focused on making complex economic topics easy to understand for everyone.
